SCHEMBL4408673

SCHEMBL4408673

NS(=O)(=O)c1ccc(-n2ccnc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.76
CA1 P00915 4/20 0.67
CA2 P00918 4/20 0.67
CA9 Q16790 4/20 0.67
CA12 O43570 2/20 0.67
LMNA P02545 1/20 0.59
MAPT P10636 1/20 0.59
ENPP2 Q13822 1/20 0.55
MKNK1 Q9BUB5 1/20 0.55
MKNK2 Q9HBH9 1/20 0.55
NOTUM Q6P988 1/20 0.55
CYP3A4 P08684 3/20 0.53
MEN1 O00255 1/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
KMT2A Q03164 1/20 0.51
BAZ2B Q9UIF8 1/20 0.51
CYP2D6 P10635 1/20 0.51
PSEN1 P49768 1/20 0.51
PSEN2 P49810 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23088859 0.87 CHRNA7 (1.00) CHRNA7CA1CA2CA9CA12
SCHEMBL23088860 0.87 CHRNA7 (1.00) CHRNA7CA1CA2CA9CA12
SCHEMBL9594739 0.84 NOTUM (0.61) CHRNA7CA1CA2CA9CA12
SCHEMBL8797691 0.82 MAOA (0.61) CHRNA7CA1CA2CA9CA12
SCHEMBL10423949 0.82 ENPP2 (0.59) CHRNA7CA1CA2CA9CA12
SCHEMBL8797045 0.80 IDO1 (0.59) CHRNA7CA1CA2CA9CA12
SCHEMBL2532397 0.80 LMNA (0.78) LMNAMAPTENPP2MKNK1MKNK2
SCHEMBL9451337 0.78 CA2 (0.66) CHRNA7CA1CA2CA9LMNA
Hydrochloric Acid SCHEMBL28701756 0.78 LMNA (0.75) LMNAMAPTENPP2MKNK1MKNK2
SCHEMBL6514849 0.78 PTGS2 (0.73) CA1CA2CA9CA12LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11040998-B2 Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2021-06-22 US disclosed
US-20200109164-A1 BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF ENANTA PHARM INC (US) 2020-04-09 US disclosed
US-10457703-B2 Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2019-10-29 US disclosed
US-20160289262-A1 BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2016-10-06 US disclosed
US-20160289262-A1 BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2016-10-06 US disclosed
US-8476456-B2 Process for the preparation of 4-(imidazol-1-yl)benzenesulfonamide derivatives PALAU PHARMA, S.A. (ES) 2013-07-02 US disclosed
US-8476456-B2 Process for the preparation of 4-(imidazol-1-yl)benzenesulfonamide derivatives PALAU PHARMA, S.A. (ES) 2013-07-02 US disclosed
US-8476456-B2 Process for the preparation of 4-(imidazol-1-yl)benzenesulfonamide derivatives PALAU PHARMA, S.A. (ES) 2013-07-02 US disclosed
US-20090012307-A1 Process for the Preparation of 4-(imidazol-1-yl)benzenesulfonamide Derivatives PALAU PHARMA, S.A. (ES) 2009-01-08 US disclosed
US-20090012307-A1 Process for the Preparation of 4-(imidazol-1-yl)benzenesulfonamide Derivatives PALAU PHARMA, S.A. (ES) 2009-01-08 US disclosed
US-7351836-B2 Antiinflammatory agents PALAU PHARMA, S.A. (ES) 2008-04-01 US disclosed
US-7351836-B2 Antiinflammatory agents PALAU PHARMA, S.A. (ES) 2008-04-01 US disclosed
US-7351836-B2 Antiinflammatory agents PALAU PHARMA, S.A. (ES) 2008-04-01 US disclosed
US-20040242872-A1 Method of preparing 4-(imidazole-1-yl)benzenesulphonamide derivatives PALAU PHARMA, S.A. (ES) 2004-12-02 US disclosed
US-20040242872-A1 Method of preparing 4-(imidazole-1-yl)benzenesulphonamide derivatives PALAU PHARMA, S.A. (ES) 2004-12-02 US disclosed
US-20040242872-A1 Method of preparing 4-(imidazole-1-yl)benzenesulphonamide derivatives PALAU PHARMA, S.A. (ES) 2004-12-02 US disclosed
EP-1424329-A1 METHOD OF PREPARING 4-(IMIDAZOLE-1-IL)BENZENESULPHONAMIDE DERIVATIVES J. Uriach & Cia. S.A. (ES) 2004-06-02 EP disclosed
EP-1424329-A1 METHOD OF PREPARING 4-(IMIDAZOLE-1-IL)BENZENESULPHONAMIDE DERIVATIVES J. Uriach & Cia. S.A. (ES) 2004-06-02 EP disclosed
WO-2003016285-A8 METHOD OF PREPARING 4-(IMIDAZOLE-1-IL)BENZENESULPHONAMIDE DERIVATIVES URIACH & CIA SA J (ES) 2003-08-28 WO disclosed
WO-2003016285-A1 METHOD OF PREPARING 4-(IMIDAZOLE-1-IL)BENZENESULPHONAMIDE DERIVATIVES J. URIACH & CIA. S.A. (ES) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11040998-B2 Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof GPBAR1, NR1H4, SLC10A1 CHRNA7 2654/4885CA1 1773/4885CA2 1361/4885
US-20090012307-A1 Process for the Preparation of 4-(imidazol-1-yl)benzenesulfonamide Derivatives IL1B, IL1A, TBXAS1 CHRNA7 4505/4885CA1 4776/4885CA2 4485/4885
US-20040242872-A1 Method of preparing 4-(imidazole-1-yl)benzenesulphonamide derivatives IL1B, IL1A, IRAK1 CHRNA7 4561/4885CA1 4607/4885CA2 4236/4885
US-20160289262-A1 BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF GPBAR1, NR1H4, SLC10A1 CHRNA7 2654/4885CA1 1773/4885CA2 1361/4885
US-20200109164-A1 BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF GPBAR1, NR1H4, SLC10A1 CHRNA7 2654/4885CA1 1773/4885CA2 1361/4885
US-10457703-B2 Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof GPBAR1, NR1H4, SLC10A1 CHRNA7 2654/4885CA1 1773/4885CA2 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.